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Abstract
Activation of the skeletal muscle ryanodine receptor (RyR1) complex results in the rapid release of Ca2+ from the
sarcoplasmic reticulum and muscle contraction. Dissociation of the small FK506 binding protein 12 subunit (FKBP12)
increases RyR1 activity and impairs muscle function. The 1,4-benzothiazepine derivative JTV519, and the more specific
derivative S107 (2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine), are thought to improve skeletal muscle
function by stabilizing the RyR1-FKBP12 complex. Here, we report a high degree of nonspecific and specific low affinity
[3H]S107 binding to SR vesicles. SR vesicles enriched in RyR1 bound ,48 [3H]S107 per RyR1 tetramer with EC50 ,52 mM and
Hillslope ,2. The effects of S107 and FKBP12 on RyR1 were examined under conditions that altered the redox state of RyR1.
S107 increased FKBP12 binding to RyR1 in SR vesicles in the presence of reduced glutathione and the NO-donor NOC12,
with no effect in the presence of oxidized glutathione. Addition of 0.15 mM FKBP12 to SR vesicles prevented FKBP12
dissociation; however, in the presence of oxidized glutathione and NOC12, FKBP12 dissociation was observed in skeletal
muscle homogenates that contained 0.43 mM myoplasmic FKBP12 and was attenuated by S107. In single channel
measurements with FKBP12-depleted RyR1s, in the absence and presence of NOC12, S107 augmented the FKBP12-
mediated decrease in channel activity. The data suggest that S107 can reverse the harmful effects of redox active species on
SR Ca2+ release in skeletal muscle by binding to RyR1 low affinity sites.
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Introduction
The ryanodine receptors (RyRs) are ion channels that release
Ca2+ from the sarcoplasmic reticulum (SR) in response to an
action potential in skeletal and cardiac muscle. RyRs are
2,200 kDa multi-protein complexes composed of four 560-kDa
RyR subunits, four small FK506 binding protein (FKBP) subunits
and additional associated proteins [1–4]. RyRs are regulated by
multiple endogenous effectors that include Ca2+, Mg2+, ATP,
protein kinases and redox active species [1–4].
FKBP12 associates predominantly with the skeletal muscle
isoform to regulate RyR1 function. FKBP12.6 binds with higher
affinity to the cardiac muscle isoform RyR2 to modulate cardiac
muscle SR Ca2+ release [5]. FKBPs belong to a family of
immunophilins that exhibit cis/trans isomerase activity. Pharma-
cological removal of FKBPs using rapamycin or FK506, causes the
dissociation of FKBP12 and FKBP12.6 from the RyR macromo-
lecular complexes, uncouples RyR ion channels from their
neighbors and activates Ca2+ release from SR [6–9]. In lipid
bilayers, rapamycin and FK506 increase channel activity and lead
to the formation of channel openings with reduced conductance
which are referred to as substates [6,7]. Two studies reported that
elimination of FKBP12 binding to RyR1 decreased voltage-gated
SR Ca2+ release in myotubes [10] and fast skeletal muscle fibers
[11].
RyR1 and RyR2 channels are subject to post-translational
modifications in skeletal and cardiac muscle. In failing hearts,
PKA-mediated hyperphosphorylation removed FKBP12.6 from
RyR2 and increased channel activity [12]. In a mouse skeletal
muscle model of heart failure and in patients with heart disease,
exercise was linked to hyperphosphorylation and depletion of
FKBP12 from RyR1 that results in increased channel activity and
decreased exercise capacity [13,14]. These findings suggested that
hyperphosphorylation and dissociation of the small FKBP subunits
(also referred to as calstabins) from RyRs result in leaky SR Ca2+
channels and impaired muscle function [15]. However, other
laboratories failed to support this proposal [16–19]. In addition to
PKA-mediated phosphorylation, mechanisms implicated in the
generation of leaky Ca2+ release channels include oxidation and S-
nitrosylation, and dissociation of FKBPs from RyR1 and RyR2. In
dystrophic muscle, increased S-nitrosylation of RyR1 [20] and
RyR2 [21] resulted in partial dissociation of FKBPs, and the
formation of leaky Ca2+ channels. Gonzalez et al. [22] reported
that elimination of neuronal nitric oxide synthase (nNOS), which is
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closely associated with RyR2 in cardiac muscle, increased diastolic
Ca2+ levels. nNOS elimination was associated with decreased S-
nitrosylation, increased oxidation of RyR2, leakage of SR Ca2+,
and arrhythmogenesis in cardiomyocytes. FKBP12.6 binding to
RyR2 and RyR2 phosphorylation were not altered in homozygous
nNOS knockout mice.
JTV519, a 1,4-benzothiazepine, also known as K201, and the
more specific 2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-ben-
zothiazepine, S107, were reported to improve muscle function
by stabilizing RyR-FKBP complexes. In an early study, JTV519
reduced SR Ca2+ efflux and improved cardiac function in dogs
subjected to chronic right ventricular pacing by minimizing RyR2
phosphorylation and stabilizing the RyR2-FKBP12.6 complex
[23]. In single channel recordings, JTV519 stabilized the closed
state of RyR2 by promoting FKBP12.6 binding [24]. On the other
hand, JTV519 suppressed spontaneous Ca2+ release in the absence
of FKPB12.6 and inhibited [3H]ryanodine binding to the RyR2-
N4104K mutant that is linked to ventricular tachycardia [25].
In recent studies, S107, the RyR-specific derivative of JTV519,
enhanced binding of FKBP12.6 to catecholaminergic polymorphic
ventricular tachycardia (CPVT)-linked RyR2-R2474S mutant
[26], and FKBP12 to the oxidized and hypernitrosylated RyR1
[20,27,28]. Treatment with S107 partially inhibited PKA- and
H2O2-mediated release of FKBP12.6 from cardiac SR vesicles
[29] and stabilized the skeletal muscle FKBP12-RyR1 complex in
24-month old mice [28].
In the present study, [3H]S107 binding and regulation of RyR1
by FKBP12 and S107 were examined. The results indicate a low
equilibrium binding affinity of S107 to multiple RyR1 sites, and
provide insight in how FKBP12 and S107 regulate RyR1 under
reducing and oxidizing conditions.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the University of North Carolina at Chapel Hill Institutional
Animal Care and Use Committee (10-056).
Materials
S107 (HCl salt) was synthesized as described [30]. [3H]S107
was prepared by RC TRITEC AG (Teufen, Switzerland).
[3H]Ryanodine was obtained from Perkin Elmer (Boston, MA),
and N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino)ethanamine
(NOC12) from Calbiochem Life Sciences (La Jolla, CA). Protease
inhibitor cocktail was from Sigma (St Louis, MO) and FK506 from
Cayman (Ann Arbor, MI). FKBP12 monoclonal antibody was
from R&D Systems (Minneapolis, MN), anti-Cys-SNO polyclonal
from Sigma. Anti-RyR1 polyclonal antibody #6425 was prepared
by YProSci Inc. (Poway, CA). Advanced ECL detection reagent
kit was from Amersham Biosciences (Piscataway, NJ). Other
chemicals were analytical grade.
Preparation of Skeletal Muscle Homogenates and
Membrane Fractions
Whole muscle homogenates and SR membrane fractions were
obtained from leg and back muscle of 2–3 month old rabbits [31].
Rabbit muscle was homogenized at 4uC using a Waring Blender in
6.5 volumes of 0.1 M NaCl, 2 mM EDTA 0.2 mM ethylene









+FKBP12 50 4.8660.08 146.063.9
+FKBP12 50 0.5560.05 36.768.8
2FKBP12 50 5.1060.12 181.0620.4
+FKBP12 ,0.01 4.8660.08 150.4616.8
SR vesicles with low and high Bmax of [
3H]ryanodine binding were obtained as
described in Materials and Methods. Bmax of [
3H]ryanodine binding was
obtained as shown in Fig. S2A. Shown are the amounts of [3H]ryanodine
specifically bound to SR vesicles after 5 h at 24uC. Specific [3H]S107 binding to
SR vesicles was determined at 44 mM [3H]S107 and indicated free Ca2+
concentration as described in Fig. S2B. Shown are the amounts of S107
specifically bound to SR vesicles after 9 h incubation at 24uC. Data are the mean
6 SD of 3–6 determinations.
doi:10.1371/journal.pone.0054208.t001
Figure 1. [3H]S107 binding to SR vesicles. (A) Time course of total,
nonspecific and specific [3H]S107 binding to SR vesicles incubated with
0.2 mM [3H]S107 in 0.25 M KCl, 20 mM imidazole, pH 7.0, 50 mM free
Ca2+ and protease inhibitors for 1 to 9 h at 24uC. Nonspecific binding
was determined by measuring [3H]S107 binding to SR vesicles heat-
inactivated for 10 min at 95uC. Data are the mean 6 SD of 3
experiments. (B) Total, nonspecific and specific [3H]S107 binding to SR
vesicles incubated with 0.1 mM [3H]S107 and 0.1 to 100 mM S107 as
above for 7 h at 24uC. Nonspecific binding was determined as in A.
Specific binding curve was obtained using four parameter logistic
equation shown in Materials and Methods.
doi:10.1371/journal.pone.0054208.g001
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glycol-bis(b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA),
5 mM Tris maleate, pH 6.8, and protease inhibitors. A crude
membrane fraction was obtained by differential centrifugation at
4,500 rpm for 25 min using a Beckman RC3B rotor and
centrifugation of the resulting supernatant fraction at
30,000 rpm for 20 min in Ti45 Beckman rotor. After treatment
with 0.5 M KCl, membranes were placed on a 20–40% sucrose
gradient containing 0.5 M KCl and centrifuged for 16 h at
24,000 rpm in a SW28 Beckman rotor. SR vesicles with a
relatively high RyR1 content (Table 1) were recovered at 33–39%
sucrose. SR vesicles with low RyR1 content (Table 1) were isolated
in the absence of salt. Rabbit muscle was homogenized at 4uC
using a Waring Blender in 6.5 volumes of 0.3 M sucrose and
protease inhibitors. A crude membrane fraction obtained by
differential centrifugation as described above was placed on a 20–
40% sucrose gradient. After centrifugation for 16 h at 24,000 rpm
in SW28 Beckman rotor, SR vesicles were recovered at 17–24%
sucrose. Both gradient fractions were diluted with 2 volumes of
H2O. After sedimentation by centrifugation, vesicles were
suspended in 0.3 M sucrose, 10 mM KPipes, pH 7 at , 10 mg
protein/ml. Aliquots of vesicles were quick frozen and stored at
280uC before use. With the exception of Table 1, all experiments
were performed with SR vesicles recovered at 33–39% sucrose of
gradients.
Endogenous FKBP12 was removed by treating SR vesicles for
30 min at 30uC with 10 mM FK506 in 0.3 M sucrose, 0.15 M
KCl, 20 mM imidazole, pH 7.5, followed by centrifugation
through a layer of 0.5 M sucrose to remove FK506 and the
dissociated FKBP12. Removal of FKBP12 was confirmed by
immunoblot analysis. Similar results were obtained by incubating
vesicles with 10 mM FK506 for 30 min at 37uC in absence of KCl
as described previously [32]. Aliquots were quick frozen and stored
at 280uC.
Preparation of Supernatant Fraction
Rabbit skeletal muscle was homogenized at 4uC in 3 volumes of
0.1 M NaCl, 20 mM imidazole, pH 7, and protease inhibitors
using a Tekmar Tissumizer for 367 s at 13,500 rpm. A
supernatant fraction was prepared by centrifuging homogenates
for 45 min at 35,000 rpm in a Beckman Ti50 rotor.
FKBP12 Preparation
Recombinant rabbit FKBP12 engineered with an amino-
terminal GST tag and TEV protease cleavage site was purified
from E. coli using GST and Q-Sepharose chromatography.
Following buffer exchange into phosphate buffered saline and
cleavage of the GST affinity tag by the addition of histidine-tagged
TEV protease, the cleaved FKBP12 protein was passed through
nickel and GST-Sepharose columns to remove the histidine-
tagged TEV protease and cleaved GST tag.
[3H]S107 Binding
[3H]S107 binding to SR vesicles was determined at 24uC using
a centrifugation assay. Unless otherwise indicated, SR vesicles
were incubated with 0.1 mM [3H]S107 and 0.1 to 100 mM
unlabelled S107 in 0.25 M KCl, 20 mM imidazole, pH 7.0
containing 50 mM free Ca2+ and protease inhibitors, followed by
centrifugation in a Beckman Airfuge for 30 min at 90,0006g.
Nonspecific binding was determined by measuring [3H]S107
binding to SR vesicles incubated for 10 min at 95uC. Bound
[3H]S107 was determined by scintillation counting after solubili-
sation of pellets in 50 mM Tris-HCl, pH 8.5 containing 2% SDS.
Specific binding parameters were calculated using the four
parameter logistic equation (SigmaPlot11).
Y~ min z( max { min )=(1z(x=EC50)̂ ({Hillslope))
where Y is specifically bound S107 per mg protein, min and max
are the minimal and maximal S107 binding values per mg protein,
respectively, x is the free S107 concentration, EC50 is the
concentration of S107 that results in half-maximal binding, and
the Hillslope represents an apparent nH.
Figure 2. Effects of FK506 and S107 on FKBP12 dissociation
from SR vesicles in the presence of GSH and GSSG. (A)
Representative immunoblot of SR vesicles not treated and treated with
FK506. SR vesicles were incubated with 10 mM FK506 as described in
Materials and Methods, followed by centrifugation to remove FK506
and dissociated FKBP12. (B and C) FKBP12 dissociation from SR vesicles
in the presence of GSH and GSSG. Immunoblots of SR vesicles not
treated with FK506 were incubated for 1 and 20 h at 24uC in 0.25 M KCl,
20 mM imidazole, pH 7.0, 50 mM free Ca2+, protease inhibitors, and the
indicated concentrations and ratios (5 mM total glutathione) of GSH
and GSSG in the absence and presence of 44 mM S107. Free FKBP12 was
removed by centrifugation. Data were normalized to SR vesicles not
incubated (gray bar, 0 min) and are the mean 6 SEM of 4–5
experiments. *p,0.05 compared to SR vesicles at 0 min not treated
with S107.
doi:10.1371/journal.pone.0054208.g002
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Distribution Coefficient of [3H]S107
The differential solubility of 0.1 mM [3H]S107 between an
aqueous and hydrophobic phase was measured using equal
volumes 0.25 M KCl, 50 mM Ca2+, 20 mM imidazole, pH 7.0
solution and vegetable oil. The two phases were mixed vigorously
and separated by centrifugation. Measurement of 3H radioactivity
in the two phases by liquid scintillation counting yielded a
distribution coefficient of 0.6160.05 (n = 2) between the hydro-
phobic and aqueous phases.
Single Channel Recordings
Single channel measurements were performed at 24uC in planar
lipid bilayers containing 5:3:2 ratio of phosphatidylethanolamine,
phosphatidylserine, and phosphatidylcholine (25 mg of total
phospholipid/ml of n-decane) [33]. SR vesicles were added to
the cis cytoplasmic side of the bilayer, with the trans SR luminal
side defined as ground. Measurements were made using 0.25 M
Cs methanesulfonate, 10 mM CsHepes, pH 7.4 on both sides of
the bilayer to minimize K+ and Cl2 channel activities in SR
vesicles [34]. Data acquired using test potentials of 635 mV were
sampled at 10 kHz and filtered at 2 kHz. Channel open
probability (Po) was determined from at least 2 min of recordings
for each condition.
[3H]Ryanodine Binding
The plant alkaloid ryanodine is widely used as a highly specific
probe of RyR channel activity because it preferentially binds the
open channel configuration [35]. In the present study a relatively
low concentration of [3H]ryanodine was used to detect changes in
binding and thus RyR1 activity. SR vesicles were incubated with
3 nM [3H]ryanodine at 24uC in 0.25 M KCl, 20 mM imidazole,
pH 7.0 with ,7 mM free Ca2+ and protease inhibitors. Nonspe-
Figure 3. FKBP12 dissociation from SR vesicles in the presence of NOC12. (A–C) SR vesicles not treated with FK506 were incubated for 5 h
at 24uC with or without 0.10 mM NOC12 in the absence and presence of 44 mM S107 in 0.25 M KCl, 20 mM imidazole, pH 7.0, 7 mM free Ca2+ and
protease inhibitors. S-nitrosylation was stopped by centrifugation. Resuspended samples were separated on 8–20% (FKBP12) and 3–12% (RyR1 and
Cys-SNO) gradient SDS-PAGE gels and transferred to nitrocellulose membranes to detect S-nitrosylation of RyR1, and FKBP12 and RyR1 proteins. Data
are the mean 6 SEM of 4 determinations. *p,0.05 compared to control samples (B) and samples with NOC12 and S107 (C). (D and E) SR membranes
were incubated with and without 44 mM S107 and 0.1 mM NOC12 at 24uC for 90 min, solubilized, and immunoprecipitated as described in Methods.
Immunoblots of RyR1 and FKBP12 are shown. Data are the mean 6 SEM of 4 experiments. *p,0.05 compared to control samples and samples
incubated with NOC12 and S107.
doi:10.1371/journal.pone.0054208.g003
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cific binding was determined using 1000-fold excess of unlabelled
ryanodine. Aliquots of samples were diluted 9-fold with ice-cold
water and placed on Whatman GF/B filters saturated with 2%
polyethyleneimine. Filters were washed with three 5-ml volumes of
ice-cold 0.1 M KCl, 1 mM K-Pipes, pH 7.0. Radioactivity
remaining on the filters was determined by liquid scintillation
counting to obtain bound [3H]ryanodine.
Bmax values of [
3H]ryanodine binding were determined by
incubating SR vesicles at 24uC with a near saturating concentra-
tion of 20 nM [3H]ryanodine in 20 mM imidazole, pH 7.0, 0.6 M
KCl, 0.15 M sucrose, protease inhibitors, and 0.1 mM Ca2+.
Nonspecific binding was determined using a 1000 to 2000 fold
excess of unlabeled ryanodine.
SDS-PAGE and Immunoblot Analysis
RyR1 was detected using 3–12% gradient SDS-PAGE and
transfer to nitrocellulose membranes. Experiments for detection of
S-nitrosocysteines were performed under nonreducing conditions
[36]. Membranes were blotted with 2% ECL Advance blocking
reagent in 0.5% Tween 20, Tris buffered saline (TBS), pH 7.4 at
24uC for 2 h. Membranes were probed with primary anti-Cys-
SNO polyclonal antibody and secondary peroxidase-conjugated
anti-rabbit IgG antibody, and with anti-RyR1 polyclonal antibody
and peroxidase-conjugated anti-mouse IgG, using the ECL
detection method. FKBP12 was detected using 8–20% gradient
SDS-PAGE and anti-FKBP12 monoclonal antibody.
Coimmunoprecipitation of RyR1 and FKBP12
For co-immunoprecipitation experiments, SR membranes were
incubated with and without 44 mM S107 and 0.1 M NOC12 at
24uC for 90 min and solubilized at 2 mg protein/ml in 15 mM
NaPipes pH 7.2 containing 0.5 M sucrose, 1 M NaCl, 2.5%
Triton X-100 and protease inhibitors [16]. Following incubation
for 10 min on ice, samples were diluted with equal volumes of ice-
cold water, incubated for another 20 min on ice, and centrifuged
for 10 min at 13,000 rpm. After dilution to 0.125 M NaCl and
0.3% Triton X-100 and addition of 0.9 mM Ca2+, the supernatant
fraction was incubated with RyR1 monoclonal antibody D286
Figure 4. Effects of NOC12 and S107 on [3H]ryanodine binding to RyR1. (A) Dependence of [3H]ryanodine binding on NOC12 concentration.
SR vesicles not treated with FK506 were incubated for 5 h at 24uC in 0.25 M KCl, 20 mM imidazole, pH 7.0, 7 mM free Ca2+, protease inhibitors and the
indicated concentrations of NOC12 in the presence (N) and absence (#) of 44 mM S107. Data are the mean 6 SEM of 4 experiments. *p,0.05
compared to vesicles without S107. (B) Dependence of [3H]ryanodine binding to RyR1 on S107 concentration. SR vesicles were incubated as in A in
the absence (#) and presence of 50 mM NOC12 (N) and the indicated concentrations of S107. Data are the mean 6 SEM of 4 experiments. *p,0.05
compared to vesicles with 50 mM NOC12 and without S107. (C) Specific [3H]ryanodine binding to SR vesicles containing (2FK506) and depleted
(+FK506) of FKBP12. [3H]Ryanodine binding was determined in the presence of 50 mM NOC12 and the absence and presence of 44 mM S107. Data are
the mean 6 SEM of 8 experiments. *p,0.05 compared to vesicles treated with FK506 and incubated in the absence of S107, #p,0.05 compared to
vesicles not treated with FK506 and incubated in the absence of S107.
doi:10.1371/journal.pone.0054208.g004
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(1:10 dilution) for 20 h at 4uC. Protein G coupled to magnetic
beads was added and samples were incubated for 2 h at 4uC. After
washing twice with 20 mM NaPipes, pH 7.2 containing 0.125 M
NaCl, 0.3% Triton X-100 and protease inhibitors, bound proteins
were released with 30 ml 46 SDS buffer at 37uC for 20 min and
separated on SDS gels and analyzed on immunoblots as described
above.
Biochemical Assays and Data Analysis
Free Ca2+ concentrations were determined by adding the
appropriate amounts of Ca2+ and EGTA calculated using stability
constants and a published computer program [37]. Free Ca2+
concentrations were verified with the use of a Ca2+ selective
electrode. Unless otherwise indicated, differences between samples
were analyzed by one-way Anova followed by Tukey t-test;
p,0.05 was considered significant.
Results
[3H]S107 Binding to SR Vesicles
A distribution coefficient of 0.61 (see Materials and Methods)
suggests that S107 can be taken up by cells and partition into the
large RyR complexes. The time course of total and nonspecific
[3H]S107 binding was determined by incubating SR vesicles
enriched in RyR1 with 0.2 mM [3H]S107 for 1 to 9 h at 24uC.
Specific [3H]S107 binding to the vesicles reached a maximum
after ,7 h (Fig. 1A). A similar time course of specific [3H]S107
binding was observed when SR vesicles were incubated with 2 mM
[3H]S107 and 20 mM [3H]S107 (Fig. S1).
Equilibrium binding of [3H]S107 was determined in a
homologous competition assay. SR vesicles were incubated for
7 h with 0.1 mM [3H]S107 in the presence of 0.1 mM to 100 mM
unlabelled S107. Total, nonspecific and specific [3H]S107 binding
are shown in Fig. 1B. Analysis of specific binding using a four
parameter logistic equation (see Methods) showed SR vesicles
bound 353646 pmol [3H]S107/mg protein (n = 93, p,0.0001)
with EC50 = 51.868.8 mM S107 (p,0.0001) and Hill-
slope = 2.160.4 (p,0.0001). A Hillslope of 2.1 reflected low
cooperativity among multiple S107 binding sites. The Bmax of
Figure 5. Effect of S107 on the stability of FKBP12-RyR1
complex in skeletal muscle homogenates. (A and B) Skeletal
muscle homogenates were incubated without (control) or with 5 mM
GSH, 5 mM GSSG or 0.10 mM NOC12 in the absence or presence of
44 mM S107 for 20 h at 24uC. Unbound FKBP12 was removed by
centrifugation and the amounts of RyR1 and FKBP12 were detected
using anti-RyR1 and anti-FKBP12 antibodies. Homogenates incubated
without glutathione and NOC12 served as control. Data are the mean 6
SEM of 8 experiments. *p,0.05 compared to control homogenates
without S107. #p,0.05 compared to homogenates incubated with
NOC12 in the absence of S107.
doi:10.1371/journal.pone.0054208.g005
Figure 6. Effects of S107 on FKBP12 binding to RyR1. (A)
Immunoblots of RyR1 and FKBP12. SR vesicles depleted of FKBP12 were
incubated for 20 h at 24uC in 0.25 M KCl, 20 mM imidazole, pH 7.0,
7 mM free Ca2+, protease inhibitors and 10 nM FKBP12 without or with
44 mM S107 in the absence and presence of 5 mM GSH, 5 mM GSSG or
0.10 mM NOC12. SR vesicles not treated with FK506 and incubated
without glutathione served as control. (B) SR vesicles not treated with
FK506 served as control. Data are the mean of 5–7 experiments.
*p,0.05 compared to FKBP12-depleted vesicles incubated without
S107 in the presence of GSH and NOC12, respectively, as determined by
paired Student’s t-test.
doi:10.1371/journal.pone.0054208.g006
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specific [3H]S107 binding exceeded the Bmax of specific [
3H]rya-
nodine binding (7.360.3 pmol/mg protein, Fig. S1A), which is a
measure of RyR1 content of the vesicles [35].
The high number [3H]S107 binding sites (350 sites/7.3 RyR1
or 48 S107 binding sites/RyR1 tetramer) suggested that [3H]S107
bound to RyR1 and other SR proteins. We tested this at 44 mM
[3H]S107. The time course of [3H]S107 binding to SR vesicles
containing relatively high and low RyR1 concentrations (4.86 and
0.55 pmol [3H]ryanodine/mg protein, respectively, Fig. S2) was
compared. SR vesicles with low RyR1 content maximally bound
36.7 pmol [3H]S107/mg protein after incubation of 1 h (Fig. S2,
Table 1). [3H]S107 bound more slowly to vesicles with higher
RyR1 content, with near maximal binding level of 146 pmol/mg
protein after 9 h incubation. Comparison of the binding data
suggested that in SR vesicles with high RyR1 content, 80–85% of
[3H]S107 was bound to RyR1. This corresponded to about 25
[3H]S107 molecules per RyR1 tetramer, with the remaining 15–
20% bound to other SR components. In SR vesicles with low
RyR1 content, ,38% of [3H]S107 was sequestered by RyR1,
assuming the binding of 25 [3H]S107 per RyR1 at 44 mM
[3H]S107.
When SR vesicles were treated with FK506 to remove FKBP12
(Fig. 2A), a similar time course of [3H]S107 binding was observed
with similar amounts of [3H]S107 bound to SR vesicles containing
or depleted of FKBP12 (Fig. S2, Table 1). A slower time course of
[3H]S107 binding was observed when vesicles were incubated in
the presence of free Ca2+ that closed (,0.01 mM Ca2+) compared
to partially activated (50 mM Ca2+) RyR1 (Fig. S2, Table 1).
However, similar amounts of [3H]S107 were bound to the SR
vesicles after incubation of 9 h. We conclude that neither the
removal of FKBP12 nor a change in RyR1 activity altered
[3H]S107 binding to RyR1.
Effects of S107 on Stability of FKBP12-RyR1 Complex in
the Absence of Exogenous FKBP12
RyR1s are redox-sensitive Ca2+ channels whose activity is
modulated by reduced (GSH) and oxidized (GSSG) glutathione
[38–40]. To determine the effect of S107 on the stability of the
FKBP12-RyR1 complex under reducing and oxidizing conditions,
SR vesicles were incubated in the presence of 5 mM GSH or
5 mM GSSG for 1 h and 20 h (Figs. 2B and C). After 1 h in the
presence of GSH, 44 mM S107 blocked the release of 10–15% of
vesicle-associated FKBP12. Similar amounts (20%) of FKBP12
Figure 7. Time course of FKBP12 binding in the presence and absence of S107. (A) Immunoblots of RyR1 and FKBP12. SR vesicles treated
with FK506 were incubated in 0.25 M KCl, 20 mM imidazole, pH 7.0, 7 mM free Ca2+, protease inhibitors and 1 mM FKBP12 for the indicated times in
the presence of 5 mM GSH, and absence or presence of 44 mM S107. FKBP12 binding was stopped by centrifugation. (B) Data are the mean 6 SEM of
7 experiments. They were corrected for amounts of FKBP12 associated with FK506 treated SR vesicles kept on ice and normalized to SR vesicles not
treated with FK506 (gray bar). *p,0.05 compared to SR vesicles not treated with FK506 and not incubated with FKBP12 and S107. #p,0.05
compared to FKBP12-depleted SR vesicles incubated for the same time (10 min or 2 h) in the presence of FKBP12 but absence of S107.
doi:10.1371/journal.pone.0054208.g007
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were released after 20 h in the presence and absence of S107. In
the presence of 5 mM GSSG, significantly larger amounts of
FKBP12 were released from the vesicles (35% and 95% after
incubation for 1 h and 20 h, respectively). Addition of 44 mM
S107 did not alter FKBP12 release from RyR1 in the presence of
5 mM GSSG (Figs. 2B and C).
The activity of RyR1 depends on the GSH/GSSG ratio
[38,39]. Incubation of SR vesicles for 20 h with 4.5 mM GSH and
0.5 mM GSSG (9:1 GSH/GSSG) released amounts of FKBP12
similar to vesicles incubated with 5 mM GSH in the presence and
absence of 44 mM S107 (Fig. 2C). About half of FKBP12 content
was released from SR vesicles after incubation for 20 h at GSH/
GSSG ratio of 4:1. Taken together, Fig. 2C shows that a decrease
in the GSH/GSSG ratio decreased the stability of the FKPB12-
RyR1 complex.
NO and the NO donor NOC12 activate RyR1 by S-
nitrosylation of a single cysteine residue (Cys3635) [36,41].
Figs. 3A–C show that treatment of SR vesicles with 0.10 mM
NOC12 significantly increased RyR1 S-nitrosylation and de-
creased FKBP12 association with SR vesicles. S107 increased the
amount of FKBP12 bound to NOC12-treated vesicles (Fig. 3C)
without altering Cys-NO content (Fig. 3B). This suggested that
S107 increased the binding affinity of FKBP12 to the S-
nitrosylated RyR1.
NOC12- and S107-treated vesicles were solubilized, and RyR1
and FKBP12 co-immunoprecipitated using an antibody against
RyR1. Immunoblots indicate that the presence of S107 minimized
the dissociation of FKBP12 from the RyR1-FKBP12 complex in
SR membranes treated with NOC12 (Figs. 3D and E).
Figure 8. Single channel measurements in the absence and presence of FKBP12 and S107. (A) SR vesicles not treated (top trace) or
treated with FK506 (traces 2 and 5) were incubated for 30 min at 24uC without addition (traces 1 and 2), with 25 mM S107 (trace 3), 5 mM FKBP12
(trace 4) or 25 mM S107 plus 5 mM FKBP12 (bottom trace) in 0.3 M sucrose, 0.25 M KCl, 20 mM imidazole, pH 7.0, and protease inhibitors. Vesicles
were then fused to a lipid bilayer and recorded at 2 mM cis cytoplasmic Ca2+ and 235 mV as described in Materials and Methods. Representative
single channel currents (downward deflections from closed levels, c–) (left) and current histograms (right) are shown. (B) Single channel data were
obtained as described in A. Data are the mean 6 SEM of 4–12 single channel recordings. *p,0.05 compared to RyR1 not treated with FK506 in the
absence of S107 and FKBP12. #p,0.05 compared to FK506-treated RyR1 incubated in the absence of S107 and FKBP12. %p,0.05 compared to FK506-
treated RyR1 incubated with FKBP12 in absence of S107. p values were determined by Student’s t-test.
doi:10.1371/journal.pone.0054208.g008
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The effects of NOC12 and S107 on RyR1 activity were further
investigated in a ligand binding assay using the RyR1-specific
probe ryanodine. Preferential binding [3H]ryanodine to the open
RyR1 provides an indirect measure of RyR1 activity [35]. NOC12
increased [3H]ryanodine binding, suggesting an increase in RyR1
activity at 0.03 to 0.30 mM (Fig. 4A). Activation by NOC12 was
partially inhibited by 44 mM S107. More than 10 mM S107 was
required to observe a significant decrease in NOC12-induced
increase in RyR1 activity using the [3H]ryanodine binding assay
(Fig. 4B). S107 reduced [3H]ryanodine binding to NOC12-treated
SR vesicles containing FKBP12 but not depleted of FKBP12
(Fig. 4C). Taken together, the data suggest that S107 decreased
NOC12-mediated RyR1 activation by attenuating the dissociation
of FKBP12 from RyR1.
Effect of S107 on the Stability of the FKBP12-RyR1
Complex in Skeletal Muscle Homogenates
SDS-PAGE and immunoblot analysis indicated that the
supernatant fraction of rabbit skeletal muscle homogenates
contains 0.4360.05 mM FKBP12 (n = 5) (data not shown). This
suggests, considering the 3 volume homogenization buffer, that
myoplasmic FKBP12 in rabbit skeletal muscle is ,1.7 mM, which
is in reasonable agreement with a myoplasmic FKBP12 concen-
tration of 3 mM reported previously [42]. To determine the effects
of exogenously added and myoplasmic FKBP12 on the stability of
the FKBP12-RyR1 complex under reducing and oxidizing
conditions, SR vesicles (in presence of 0.15 mM exogenous
FKBP12) or homogenates were incubated without or with
5 mM GSH, 5 mM GSSG or 0.1 mM NOC12 for 20 h.
FKBP12 did not dissociate from SR vesicles incubated with
0.15 mM FKBP12 in the presence of 5 mM GSH, 5 mM GSSG or
0.1 mM NOC12 (Fig. S3). FKBP12 was also not released from the
particulate matter of homogenates incubated for 20 h with GSH
(Fig. 5). However, in the presence of GSSG and NOC12, ,35%
and 45% FKBP12 dissociation, respectively, was observed in
homogenates with 0.43 mM myoplasmic FKBP12. Addition of
S107 increased the amount of FKBP12 associated with particulate
matter of homogenates, which suggests that S107 minimized
GSSG- and NO-mediated dissociation of FKBP12 from RyR1.
S107 Increases FKBP12 Binding to RyR1
To verify that S107 increases FKBP12 binding to RyR1,
FKBP12-depleted SR vesicles were incubated for 20 h with
10 nM FKBP12 in the absence and presence of 44 mM S107
(Fig. 6). In absence of S107, highest levels of FKBP12 binding
were seen with SR vesicles incubated in presence of 5 mM GSH,
intermediate levels with 0.1 mM NOC12, and lowest levels to SR
vesicles with 5 mM GSSG. FKBP12 binding to FKBP12-depleted
vesicles was increased by S107 in presence of GSH and NOC12
but not GSSG.
To determine how S107 affects the association rate of FKBP12
binding to RyR1, FKBP12-depleted SR vesicles were incubated
for 10 min, 2 h and 20 h with 1 mM FKBP12 in the presence of
5 mM GSH with and without 44 mM S107, followed by
immunoblot analysis (Fig. 7). The amounts of bound FKBP12
were compared with SR vesicles not treated with FK506. After
10 min, significantly greater amounts of FKBP12 were bound to
vesicles in the presence than the absence of 44 mM S107 (4967
and 3665%, respectively, of FKBP12 in SR vesicles not treated
with FK506). Incubation for 2 h significantly increased the level of
FKBP12 from 6864% in the absence of S107 to 8664% in
presence of S107. At 20 h, FKBP12 binding was similar to
untreated SR vesicles in the presence and absence of S107. That
S107 increased the rate of FKBP12 binding to FKBP12-depleted
SR vesicles was confirmed using the [3H]ryanodine binding assay
(Spplemental Information, Fig. S4).
Effects of S107 and FKBP12 on RyR1 Single Channel
Activity Using the Planar Lipid Bilayer Method
SR vesicles not treated with or exposed to FK506 to remove
FKBP12 (Fig. 2A) were fused with a lipid bilayer. Before addition
to the cis bilayer chamber, vesicles were incubated for 30 min
without and with 25 mM S107 and 5 mM FKBP12, conditions
similar to those in Fig. 7. A shorter preincubation period and lower
FKBP12 concentration resulted in smaller differences in channel
activity without and with S107, whereas longer incubations to
achieve equilibrium equalized binding in the absence and presence
of S107 (data not shown).
FKBP12-depleted RyR1 channels recorded at 2 mM cis
cytoplasmic Ca2+ exhibited a 4-fold greater single channel open
probability (Po) than RyR1 channels without FK506 (Fig. 8A,
traces 1 and 2, Fig. 8B). Removal of FKBP12 from the RyR1
complex is reported to result in the formation of channel openings
with reduced conductance which are referred to as substates [6].
However, current traces and current histograms of Fig. 8A (traces
1 and 2) show that removal of FKBP12 only minimally increased
the appearance of substates. A two-fold significant decrease in Po
was observed for FKBP12-depleted RyR1 channels preincubated
with FKBP12 (Fig. 8A, traces 2 and 4, Fig. 8B). A further 2-fold
significant decrease in Po was observed for vesicles preincubated
with 5 mM FKBP12 in the presence of 25 mM S107 (Fig. 8A,
traces 4 and 5, Fig. 8B). The results suggest that S107 increased
binding of FKBP12 to RyR1. In agreement with the [3H]ryano-
dine binding experiments of Fig. 4C, preincubation with 25 mM
S107 alone had no effect (Fig. 8A, traces 2 and 3, Fig. 8B). In
controls, preincubation with 25 mM S107, 5 mM FKBP12, or the
combined preincubation with 25 mM S107 and 5 mM FKBP12
had no effect on channel activities not exposed to FK506 (Fig. 8B).
Reduction of cytoplasmic Ca2+ from 2 mM to 0.1 mM decreased
Po to a similar low value for vesicles treated and not treated with
FK506 (data not shown).
Single channel measurements were also performed with SR
vesicles preincubated with 0.1 mM NOC12 (Fig. S5). As shown in
Fig. 8, S107 lowered Po of FKBP12-depleted RyR1s in the
presence but not the absence of FKBP12.
Discussion
This report describes the regulation of the skeletal muscle RyR1
ion channel by the 1,4 benzoderivative S107 and FKBP12
subunit. Previous studies suggested that S107 reverses the
deleterious effects of in vivo RyR oxidation and S-nitrosylation
on SR Ca2+ release by reducing FKBP dissociation from cardiac
muscle and skeletal muscle RyR complexes [20,28,29]. The
present study provides the first direct insights into the S107
binding characteristics of RyR1. [3H]S107 binding studies indicate
that S107 binds with micromolar affinity to multiple RyR1 sites.
Immunoblot, [3H]ryanodine binding and single channel measure-
ments showed that S107 inhibited S-nitrosylation-mediated
FKBP12 dissociation and RyR1 activation, and attenuated the
destabilizing effects of oxidized glutathione and S-nitrosylation in a
skeletal muscle homogenate.
[3H]S107 binding studies indicated a high degree of nonspecific
and specific binding, which suggests that S107 may have
additional functional effects by interacting with other SR proteins
and possibly RyR1 associated lipids. Analysis of the [3H]S107
binding data using a four parameter logistic equation suggested a
low binding affinity (EC50 ,50 mM) to RyR1. An unexpectedly
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high number of binding sites was observed that exceeded the
concentration of RyR1 in SR vesicles. Further studies are needed
to address why S107 binds slowly to RyR1, how S107 alters the
regulation of RyR1 by other endogenous effectors, and the basis of
the high number of S107 binding sites in RyR1. A distribution
coeffficient of 0.61 suggests that S107 partitions into the large
subunits of RyR1 allowing the binding to multiple sites.
Four FKBP12 molecules are bound to the homotetrameric
RyRs [32]. Dissociation of FKBP12 from the RyR1 complex
increased open channel probability (Po) and induced substates
[6,7,43,44]. In agreement with Barg at al. [45], we found that
removal of FKBP12 increased RyR1 activity at 2 mM free Ca2+,
but did not increase the frequency of RyR1 substates in single
channel measurements. The reason for this discrepancy is unclear
but may result from differences in sample preparation and
recording conditions.
The RyRs are redox-sensitive channels whose redox state and
activity depend on the glutathione redox potential and reactive
oxygen and nitrogen species [29,38,39,46–50]. There are 100
cysteine residues in the RyR1 subunit and one cysteine per
FKBP12 subunit that can be potentially modified [2]. RyR1s are
likely in a reduced state in vivo based on the reducing environment
of thiol-reducing compounds, the most abundant being glutathi-
one [51]. Unlike the RyR1 polypeptides, which are readily
modified by redox active species, the small FKBP12 subunit was
neither S-nitrosylated using NO-donor NOR-3 nor S-glutathio-
nylated by GSH and H2O2 [52]. S-nitrosylation decreased RyR1
binding affinity for FKBP12 several fold in a [35S]FKBP binding
exchange assay, whereas S-glutathionylation had no effect.
Treatment with H2O2 and diamide lowered FKBP12 binding to
RyR1 [53]. In the present study with SR vesicles in the absence of
exogenously added FKBP12, oxidation resulted in FKBP12
dissociation from the RyR1 complex when free thiol content was
decreased from 37.561.0 thiols/RyR1 subunit in the presence of
GSH to 30.862.7 thiols/RyR1 subunit in the presence of GSSG
[54], and when one cysteine (Cys3635) per RyR1 subunit was S-
nitrosylated by the NO donor NOC12 [36,41]. The results
indicate that oxidation and S-nitrosylation of RyR1 destabilize the
FKBP12-RyR1 complex.
S107 has a significant effect on skeletal muscle function by
minimizing the release of FKPB12 from RyR1 and thereby NO-
mediated SR Ca2+ leakage during exercise [30], and oxidation and
S-nitrosylation in dystrophic and aged skeletal muscle [20].
Rapamycin-induced deleterious effects on mitochondrial function
could be prevented by treatment of FDB fibers with 5 mM S107
[28]. Daily administration of 1.3 mg S107 (,20 mmol S107/kg)
for 4 weeks improved muscle function and exercise capacity in
WT but not FKBP122/2 mice [28]. We found that S107
increased FKBP12 binding to RyR1 incubated with the NO
donor NOC12. Greater than 10 mM S107 was required to
significantly inhibit NOC12-mediated activation of RyR1. This
was in agreement with the [3H]S107 binding studies, which
showed that S107 binds with low affinity to RyR1. Removal of
FKBP12 from SR vesicles did not appreciably alter [3H]S107
binding, which suggests that S107 binding did not depend on
FKBP12.
Previous immunoprecipitation and immunoblot experiments
showed that treatment of mice with S107 stabilized binding of
FKBP12 to RyR1 without attenuating RyR1 oxidation and S-
nitrosylation in skeletal muscle of 24-month-old mice [28]. We
observed GSSG- and NO-mediated dissociation of FKBP12 when
SR vesicles were incubated in the absence of FKBP12. Presence of
0.15 mM FKBP12 eliminated the dissociation of FKBP12 from SR
vesicles. However, GSSG- and NO-mediated dissociation was
observed in skeletal muscle homogenates that contained 0.43 mM
myoplasmic FKBP12. At this time, the mechanism(s) leading to
the dissociation of FKBP12 in homogenates remains unclear. One
possibility we cannot rule out is that binding of FKBP12 to
myoplasmic proteins decreases the free FKBP12 concentration. In
this case, FKBP12 could dissociate from RyR1, and S107 could
attenuate dissociation of FKBP12 by increasing FKBP12 binding
affinity to RyR1. Another possibility is that unknown factors lead
to the release of FKBP12 in homogenates. Further studies will
address the mechanism(s) for the release of FKBP12 and enable
S107 to stabilize the FKBP12-RyR1 complex in skeletal muscle.
Conclusion
The present study shows that S107 binds to multiple RyR1 sites
with low affinity. Stabilization of the RyR1-FKBP12 complex by
S107 depended on the redox state of RyR1. In homogenates,
GSSG- and NO-mediated dissociation of FKBP12 occurred in the
presence of a relatively high myoplasmic FKBP12 concentration,
which suggests that other to be identified factors may be involved
in destabilization of the FKBP12-RyR1 complex in skeletal
muscle. Reduction of NOC12-mediated release of FKBP12 by
S107 in homogenates is of interest, because NO-mediated RyR1
S-nitrosylation triggers the release of Ca2+ in brain [55] and
skeletal muscle [20,28,56] under physiological and pathological
conditions.
Supporting Information
Figure S1 Time course of specific [3H]ryanodine and
[3H]S107 binding to SR vesicles. (A) Specific [3H]ryanodine
binding to SR vesicles was determined as described in Materials
and Methods. Data are the mean 6 SEM of 6 experiments. (B) SR
vesicles were incubated for the indicated times at 24uC with 2 mM
(N) and 20 mM (#) [3H]S107 in 0.25 M KCl, 20 mM imidazole,
pH 7.0, 50 mM free Ca2+ and protease inhibitors. Non-specific
binding was determined by measuring [3H]S107 binding to SR
vesicles heat-inactivated for 10 min at 95uC. Data are the mean 6
SEM of 4 experiments.
(TIF)
Figure S2 Time course of specific [3Hryanodine and
[3H]S107 binding to SR vesicles with relatively high and
low RyR1 content. (A) Specific [3H]ryanodine binding to SR
vesicles with (N,%) and without (D) FKBP12 and relatively high
and low RyR1 content was determined as described in Materials
and Methods. Bmax of [
3H]ryanodine binding were 0.5560.05
(%), 4.8660.08 (N) and 5.1060.12 (D) pmol/mg protein. Data are
the mean 6 SD of 3 experiments. (B) SR vesicles with (%,#,N) and
without FKBP12 (D) were incubated for the indicated times at
24uC with 44 mM [3H]S107 in 0.25 M KCl, 20 mM imidazole,
pH 7.0, 50 mM (%,N,D) and ,0.01 mM (#) free Ca2+ and
protease inhibitors. Nonspecific binding was determined by
measuring [3H]S107 binding to SR vesicles heat-inactivated for
10 min at 95uC. Data are the mean 6 SD of 3–6 experiments.
(JPG)
Figure S3 Stability of FKBP12-RyR1 complex in pres-
ence of 0.15 mM FKBP12. SR vesicles were incubated in
presence of 0.15 mM FKBP12 without (control) and with 5 mM
GSH, 5 mM GSSG or 0.10 mM NOC12 for 20 h at 24uC.
Unbound FKBP12 was removed by centrifugation and amounts of
RyR1 and FKBP12 were detected using anti-RyR1 and anti-
FKBP12 antibodies. Data are the mean 6 SD of 3 experiments.
(TIF)
S107 Effects on RyR1-FKBP12
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e54208
Figure S4 Effects of FKBP12 and S107 on [3H]ryanodine
binding to SR vesicles not treated and treated with
FK506. (A) Time course of specific [3H]ryanodine binding.
Vesicles treated and not treated with FK506 were incubated at
24uC for indicated times in 0.25 M KCl, 20 mM imidazole,
pH 7.0, 3 nM [3H]ryanodine, 7 mM free Ca2+, 5 mM GSH and
protease inhibitors. Removal of FKBP12 increased RyR1 activity,
as indicated by an increase in [3H]ryanodine binding. Data are the
mean 6 SD of 3–4 experiments. *p,0.05 compared to vesicles
minus FK506. (B) Effects of FKBP12 and S107 on [3H]ryanodine
binding. SR vesicles treated and not treated with FK506 were
incubated at 24uC for the indicated times in the above buffer
containing the indicated concentrations of FKBP12 and S107.
Data show that in the absence of added FKBP12, S107 did not
alter [3H]ryanodine binding to SR vesicles with (2FK506) or
freed (+FK506) of FKBP12, whereas S107 significantly decreased
[3H]ryanodine binding to FKBP12-depleted vesicles in the
presence of FKBP12 after preincubation for 10 min and 30 min.
Data are the mean 6 SEM of 4–6 experiments. *p,0.05
compared to vesicles minus FK506 at 10 and 30 min, respectively.
#p,0.05 compared to FKBP12-depleated vesicles plus added
FKBP12 and minus S107 at 10 and 30 min, respectively.
(TIF)
Figure S5 Single channel measurements with NOC12-
treated RyR1s. (A) FK506-treated SR vesicles were incubated
for 30 min at 24uC with 0.10 mM NOC12 in 0.3 M sucrose,
0.25 M KCl, 20 mM imidazole, pH 7.0 without (top trace), with
44 mMS107 (trace 2), 5 mM FKBP12 (trace 3) or 44 mM S107 plus
5 mM FKBP12 (bottom trace). Vesicles were then fused to a lipid
bilayer and recorded at 2 mM cis cytoplasmic Ca2+ and 235 mV
as described in Materials and Methods. Representative single
channel recordings (downward deflections from closed levels, c–)
(left) and current histograms (right) are shown. (B) Single channel
data were obtained as described in A. Mean channel open
probabilities (Po) were greater in the presence of NOC12 (this
figure) than absence of NOC12 (Fig. 8) by 11% in absence of S107
and FKBP12, by 11% in presence of S107, by 3% in presence of
FKBP12, and 35% in presence of S107 and FKBP12. Data are the
mean 6 SEM of 5–8 single channel recordings. *p,0.05
compared to RyR1s not incubated with S107 and FKBP12,
#p,0.05 compared to RyR1s incubated with FKBP12 in absence




Conceived and designed the experiments: YM LX HK CT GM.
Performed the experiments: YM LX GT GM. Analyzed the data: YM
LX GM. Contributed reagents/materials/analysis tools: HK GT. Wrote
the paper: YM CT GM.
References
1. Franzini-Armstrong C, Protasi F (1997) Ryanodine receptors of striated muscles:
a complex channel capable of multiple interactions. Physiol Rev 77: 699–729.
2. Meissner G (2002) Regulation of mammalian ryanodine receptors. Frontiers
Biosci 7: d2072–2080.
3. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL (2010) Ryanodine receptors:
structure, expression, molecular details, and function in calcium release. Cold
Spring Harb Perspect Biol 2: a003996.
4. Capes EM, Loaiza R, Valdivia HH (2011) Ryanodine receptors. Skeletal Muscle
1: 18.
5. Lam E, Martin MM, Timerman AP, Sabers C, Fleischer S, et al. (1995) A novel
FK506 binding protein can mediate the immunosuppressive effects of FK506
and is associated with the cardiac ryanodine receptor. J Biol Chem 270: 26511–
26522.
6. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, et al. (1994)
Stabilization of calcium release channel (ryanodine receptor) function by FK506-
binding protein. Cell 77: 513–523.
7. Ahern GP, Junankar PR, Dulhunty AF (1997) Subconductance states in single-
channel activity of skeletal muscle ryanodine receptors after removal of FKBP12.
Biophys J 72: 146–162.
8. Marx SO, Ondrias K, Marks AR (1998) Coupled gating between individual
skeletal muscle Ca2+ release channels (ryanodine receptors). Science 281: 818–
821.
9. Marx SO, Gaburjakova J, Gaburjakova M, Henrikson C, Ondrias K, et al.
(2001) Coupled gating between cardiac calcium release channels (ryanodine
receptors). Circ Res 88: 1151–1158.
10. Avila G, Lee EH, Perez CF, Allen PD, Dirksen RT (2003) FKBP12 binding to
RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes.
J Biol Chem 278: 22600–22608.
11. Tang W, Ingalls CP, Durham WJ, Snider J, Reid MB, et al. (2004) Altered
excitation-contraction coupling with skeletal muscle specific FKBP12 deficiency.
The FASEB J 18: 1597–1599.
12. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, et al. (2000) PKA
phosphorylation dissociates FKBP12.6 from the calcium release channel
(ryanodine receptor): defective regulation in failing hearts. Cell 101: 365–376.
13. Reiken S, Lacampagne A, Zhou H, Kherani A, Lehnart SE, et al. (2003) PKA
phosphorylation activates the calcium release channel (ryanodine receptor) in
skeletal muscle: defective regulation in heart failure. J Cell Biol 160: 919–928.
14. Ward CW, Reiken S, Marks AR, Marty I, Vassort G, et al. (2003) Defects in
ryanodine receptor calcium release in skeletal muscle from post-myocardial
infarct rats. FASEB J 17: 1517–1519.
15. Wehrens XH, Lehnart SE, Marks AR (2005) Intracellular calcium release and
cardiac disease. Annu Rev Physiol 67: 69–98.
16. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G (2003) Characterization
of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809)
ryanodine receptor phosphorylation mutants. J Biol Chem 278: 51693–51702.
17. Xiao B, Jiang MT, Zhao M, Yang D, Sutherland C, et al. (2005)
Characterization of a novel PKA phosphorylation site, Serine-2030, reveals
no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart
failure. Circ Res 96: 847–855.
18. Xiao J, Tian X, Jones PP, Bolstad J, Kong H, et al. (2007) Removal of
FKBP12.6 does not alter the conductance and activation of the cardiac
ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmi-
as. J Biol Chem 282: 34828–34838.
19. Li Y, Kranias EG, Mignery GA, Bers DM (2002) Protein kinase A
phosphorylation of the ryanodine receptor does not affect calcium sparks in
mouse ventricular myocytes. Circ Res 90: 309–316.
20. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, et al. (2009)
Hypernitrosylated ryanodine receptor calcium release channels are leaky in
dystrophic muscle. Nat Med 15: 325–330.
21. Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, et al. (2010) Leaky
RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc
Natl Acad Sci U S A 107: 1559–1564.
22. Gonzalez DR, Beigi F, Treuer AV, Hare JM (2007) Deficient ryanodine
receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and
arrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci U S A 104: 20612–
20617.
23. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, et al. (2003) FKBP12.6-
mediated stabilization of calcium-release channel (ryanodine receptor) as a novel
therapeutic strategy against heart failure. Circulation 107: 477–484.
24. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, et al. (2004)
Protection from cardiac arrhythmia through ryanodine receptor-stabilizing
protein calstabin 2. Science 304: 292–296.
25. Hunt DJ, Jones PP, Wang R, Chen W, Bolstad J, et al. (2007) K201 (JTV519)
suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2
irrespective of FKBP12.6 association. Biochem J 404: 431–438.
26. Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, et al. (2008)
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden
cardiac death in mice. J Clin Invest 118: 2230–2245.
27. Fauconnier J, Meli AC, Thireau J, Roberge S, Shan J, et al. (2011) Ryanodine
receptor leak mediated by caspase-8 activation leads to left ventricular injury
after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A 108: 13258–
13263.
28. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, et al.
(2011) Ryanodine receptor oxidation causes intracellular calcium leak and
muscle weakness in aging. Cell Metabolism 14: 196–207.
29. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, et al. (2010) Role of
chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic
receptor blockade in mice. J Clin Invest 120: 4375–4387.
30. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, et al. (2008)
Remodeling of ryanodine receptor complex causes ‘‘leaky’’ channels: a
molecular mechanism for decreased exercise capacity. Proc Natl Acad
Sci U S A 105: 2198–2202.
S107 Effects on RyR1-FKBP12
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e54208
31. Anderson K, Cohn AH, Meissner G (1994) High-affinity [3H]PN200-110 and
[3H]ryanodine binding to rabbit and frog skeletal muscle. Am J Physiol 266:
C462–C466.
32. Timerman AP, Ogunbumni E, Freund E, Wiederrecht G, Marks AR, et al.
(1993) The calcium release channel of sarcoplasmic reticulum is modulated by
FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the
calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem
268: 22992–22999.
33. Xu L, Tripathy A, Pasek DA, Meissner G (1999) Ruthenium red modifies the
cardiac and skeletal muscle Ca2+ release channels (ryanodine receptors) by
multiple mechanisms. J Biol Chem 274: 32680–32691.
34. Meissner G (1983) Monovalent ion and calcium ion fluxes in sarcoplasmic
reticulum. Mol Cell Biochem 55: 65–82.
35. Sutko J L, Airey JA, Welch W, Ruest L (1997) The pharmacology of ryanodine
and related compounds. Pharmacol Rev 49: 53–98.
36. Sun J, Xin C, Eu JP, Stamler JS, Meissner G (2001) Cysteine-3635 is responsible
for skeletal muscle ryanodine receptor modulation by NO. Proc Natl Acad Sci U
S A 98: 11158–11162.
37. Schoenmakers TJ, Visser GJ, Flik G, Theuvenet AP (1992) CHELATOR: an
improved method for computing metal ion concentrations in physiological
solutions. BioTechniques 12: 870–879.
38. Zable AC, Favero TG, Abramson JJ (1997) Glutathione modulates ryanodine
receptor from skeletal muscle sarcoplasmic reticulum. Evidence for redox
regulation of the Ca2+ release mechanism. J Biol Chem 272: 7069–7077.
39. Feng W, Liu G, Allen PD, Pessah IN (2000) Transmembrane redox sensor of
ryanodine receptor complex. J Biol Chem 275: 35902–35907.
40. Balshaw DM, Xu L, Yamaguchi N, Pasek DA, Meissner G (2001) Calmodulin
binding and inhibition of cardiac muscle calcium release channel (ryanodine
receptor). J Biol Chem 276: 20144–20153.
41. Sun J, Xu L, Eu JP, Stamler JS, Meissner G (2003) Nitric oxide, NOC-12, and
S-nitrosoglutathione modulate the skeletal muscle calcium release channel/
ryanodine receptor by different mechanisms. J Biol Chem 278: 8184–8189.
42. Timerman AP, Wiederrecht G, Marcy A, Fleischer S (1995) Characterization of
an exchange reaction between soluble FKBP-12 and the FKBP-ryanodine
receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl
isomerase activity. J Biol Chem 270: 2451–2459.
43. Ma J, Bhat MB, Zhao J (1995) Rectification of skeletal muscle ryanodine
receptor mediated by FK506 binding protein. Biophys J 69: 2398–2404.
44. Kaftan E, Marks AR, Ehrlich BE (1996) Effects of rapamycin on ryanodine
receptor/Ca2+-release channels from cardiac muscle. Circ Res 78: 990–997.
45. Barg S, Copello JA, Fleischer S (1997) Different interactions of cardiac and
skeletal muscle ryanodine receptors with FK-506 binding protein isoforms.
Am J Physiol 272: C1726–C1733.
46. Reid MB (1996) Reactive oxygen and nitric oxide in skeletal muscle. News
Physiol Science 11: 114–121.
47. Terentyev D, Gyorke I, Belevych AE, Terentyeva R, Sridhar A, et al. (2008)
Redox modification of ryanodine receptors contributes to sarcoplasmic
reticulum Ca2+ leak in chronic heart failure. Circ Res 103: 1466–1472.
48. Eu JP, Sun J, Xu L, Stamler JS, Meissner G (2000) The skeletal muscle calcium
release channel: coupled O2 sensor and NO signaling functions. Cell 102: 499–
509.
49. Xia R, Stangler T, Abramson JJ (2000) Skeletal muscle ryanodine receptor is a
redox sensor with a well defined redox potential that is sensitive to channel
modulators. J Biol Chem 275: 36556–36561.
50. Hidalgo C, Donoso P (2008) Crosstalk between calcium and redox signaling:
from molecular mechanisms to health implications. Antioxid Redox Signal 10:
1275–1312.
51. Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol
257: L163–L173.
52. Aracena P, Tang W, Hamilton SL, Hidalgo C (2005) Effects of S-
glutathionylation and S-nitrosylation on calmodulin binding to triads and
FKBP12 binding to type 1 calcium release channels. Antioxid Redox Signal 7:
870–881.
53. Zissimopoulos S, Docrat N, Lai FA (2007) Redox sensitivity of the ryanodine
receptor interaction with FK506-binding protein. J Biol Chem 282: 6976–6983.
54. Petrotchenko EV, Yamaguchi N, Pasek DA, Borchers CH, Meissner G (2011)
Mass spectrometric analysis and mutagenesis predict involvement of multiple
cysteines in redox regulation of the skeletal muscle ryanodine receptor ion
channel complex. Res Rep Biol 2011: 13–21.
55. Kakizawa S, Yamazawa T, Chen Y, Ito A, Murayama T, et al. (2011) Nitric
oxide-induced calcium release via ryanodine receptors regulates neuronal
function. EMBO J 31: 417–428.
56. Eu JP, Hare JM, Hess DT, Skaf M, Sun J, et al. (2003) Concerted regulation of
skeletal muscle contractility by oxygen tension and endogenous nitric oxide. Proc
Natl Acad Sci U S A 100: 15229–15234.
S107 Effects on RyR1-FKBP12
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e54208
